Predictive blood test guides first-line treatment decisions for advanced unresectable non-small lung cancer patients OncoHost, a precision diagnostics company centered on predictive biomarker development for improved patient care, launched the official PROphet non-small cell lung…
Read More
Multi-Center Trial of More Than 12,000 Orthopedic Trauma Patients Likely to Change Standard of Care Patients hospitalized with fractures typically receive an injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots. A new clinical…
OMEC.AI is the first company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X OMEC.AI will use advanced machine learning…
First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic effects in solid tumor models Sheba Medical Center was recently selected as one of the…
AION Labs, Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: “Prediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient…
ARH will leverage Biofourmis’ end-to-end solution in a prestigious Rural Home Hospital program launched by joint venture of Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health Biofourmis, a global…